INDEX

Complement
- classical reaction, 127
- intermediate complexes, properties, activities and control of, 129

Complement activation
- activities and pharmacologically active products of, 125
- alternate pathways, 136
- factors involved, 142
- anaphylatoxin formation, 137
- cobra venom, 141
- guinea pig immunoglobulins, 140
- lipopolysaccharides, 139
- pathway, CI by-pass, 142
- properdin system, 136
- zymosan, 137

Complement components, peptide fragments, active, 150

Corticosterone levels, 6-hydroxydopamine effects on, 268

Diet, natural sera synthetic, 190

Dopa decarboxylase, substrate and inhibitor selectivity, 335

Dopamine-β-hydroxylase, substrate and inhibitor selectivity, 337

Dopamine receptors, criteria for investigation of, 358

Drug-metabolizing enzyme system, role of nutrition, 171

Drugs, prostaglandin biosynthesis inhibited by, 33

Eason-Stedman hypothesis, 356

Enzyme(s)
- alterations by 6-hydroxydopamine, 223
- catecholamine biosynthesis and substrate and inhibitor selectivity, 335
- metabolism, substrate and inhibitor selectivity, 337

Enzyme system, drug-metabolizing, role of nutrition in, 171

Fatty acids, inhibition of prostaglandin biosynthesis, 37

Fever
- antipyretics and, 365, 310
- brain monoamines and, 308
- hypothalamic neurons, behaviour during, 307
- prostaglandins and pyrogen action, 309
- pyrogens and, 305

Flower, Roderick J., Drugs which inhibit prostaglandin biosynthesis, 33

Food intake, 6-hydroxydopamine effects on, 260

Hayes, Johnnie. See Campbell and Hayes, 171

Heart, β-adrenergic receptor antagonists in study of cardiac arrhythmia, 368

Hellow, R. F., Monoamines, pyrogens and cations:
- Their actions on central control of body temperature, 289
- 6-Hydroxydopamine, biological effects, 268
- 6-Hydroxydopamine
- behavioral alterations produced by, 259
- cardiovascular effects, 244
- catecholamine-containing neurons, morphological alterations after treatment with, 226
- central injections, 253
- development of postsynaptic supersensitivity after treatment with, 210
- development of presynaptic supersensitivity after treatment with, 209
- differential sensitivity of catecholamine-containing neurons to, 211
- effects on adrenergic sites, 210
- audiogenic seizures, 264
- body temperature, 261
- catecholamine-containing neurons in the central nervous system, 213
- catecholamine uptake, 222
- central putative transmitters, 228
- corticosterone levels, 268
- food intake, 260
- irritability and aggression, 266
- locomotor activity, 263
- melanophores, 268
- monoamine content of central nervous system, 213
- morphine-treated mice, 264
- operant activity, 267
- peripheral autonomic structures, 230
- reproductive physiology, 265
- skin grafts, 267
- sleep, 265
- sympathetic neurons in end organs, 237
- water intake, 260
- enzyme alterations by, 223
- false neurotransmitter role and nondestructive effects of, 203
- intraneuronal sites associated with destructive lesioning of, 206
- loss of conduction properties of noradrenergic terminal endings after treatment with, 208
- maternal treatment with, 254
- molecular mechanisms of action of, 254
- neonatal effects, 254
- neuronal interactions with, temporal sequence of, 202
- organ susceptibility to, differences, 236
- peripheral injections central nervous system, 250
- sympathetic nervous system, 246
- pharmacological actions of, 199
- route of administration, 230
- selectivity of uptake into catecholamine-containing neurons, 203
Prostaglandin dehydrogenase, inhibition of, 60
Prostaglandin synthetase, distribution of, 37
Prostaglandins
antipyretics and, 311
effect on pyrogen actions, 309
Protein, effect of deficiency on mixed function oxidase system, 176
Pyrogens
action on central nervous system, effects of prostaglandins, 309
central control of body temperature, 289
composition of, 306
fevers and, 305
site of action, 306
Regoli, D., W. K. Park and F. Rioux, Pharmacology of angiotensin, 69
Rioux, F. See Regoli et al., 69
Skin grafts, 6-hydroxydopamine effects on, 267
Sleep, 6-hydroxydopamine effects on, 265
Sympathetic ganglia, angiotensin effects on, 112
Sympathetic nerve terminals, angiotensin effects on, 113
Sympathetic nervous system, 6-hydroxydopamine effects, peripheral injections, 246
Synthetase preparations, drug sensitivity, 48
Temperature transmitter substances and their central effects on, 291
evidence from various species, 292
Temperature regulation
ations, central actions of, 313
as a control system, 290
Thron, C. D., Linearity and superposition in pharmacokinetics, 3
Trendelenberg, U. See Patil et al., 323
Tyrosine hydroxylase, substrate and inhibitor selectivity, 335
Uptake, inhibition of, 348
Venom, cobra, complement activation, 141
Vitamins, effect of deficiency of, on mixed function oxidase system, 181
Vogt, Walther, Activation, activities and pharmacologically active products of complement, 125
Water intake, 6-hydroxydopamine effects, 260